Aberrant alternative splicing (AS) events have been implicated in cancer progression; however, their role in metastatic renal cell carcinoma (mRCC) remains underexplored. This study aims to identify AS events associated with clinical benefits from immune checkpoint inhibitors and targeted therapies in mRCC.
We conducted a retrospective analysis on 101 patients with mRCC who received systemic therapy and underwent RNA sequencing. Patients were divided into subgroups based on ICIs (alone or in combination) and targeted therapies. Responders and non-responders were classified according to Response Evaluation Criteria in Solid Tumors V.1.1 criteria. Differential gene expression and splicing analyses were performed between responders and non-responders in each cohort. Novel AS events were analyzed for their potential to generate peptide neoantigens through major histocompatibility complex (MHC) class I binding predictions.
Outlier splicing analysis identified 10 aberrant splice events specific to mRCC. AS analysis revealed 461 differentially spliced events between responders and non-responders in the ICI cohort and 253 in the targeted therapy cohort, with intron retention as the predominant motif. Thirteen unique AS events were enriched in responders, including PTPN6 and ACTN1. Predictive neoantigen analysis identified high MHC class I binding potential in peptides from AS events in IFFO1 and ZNF692. High splice burden was linked to an immunogenic tumor microenvironment, characterized by enriched antigen processing and adaptive immune responses.
This study provides a comprehensive analysis of AS events in mRCC, highlighting intron retention as potential biomarkers for treatment response. Identified AS-derived neoantigens may serve as potential targets for adoptive cell therapy strategies.
Journal for immunotherapy of cancer. 2026 May 05*** epublish ***
Ameish Govindarajan, Nathaniel Hansen, Benjamin D Mercier, Sara A Byron, Apurva Hegde, Krystine Garcia-Mansfield, Kristin Leskoske, Neal Chawla, Luis Meza, Zeynep Zengin, Regina Barragan-Carillo, Hedyeh Ebrahimi, Daniela V Castro, Nazli Dizman, JoAnn Hsu, Alexander Chehrazi-Raffle, Abhishek Tripathi, Nicholas J Salgia, Sumanta K Pal, Patrick Pirrotte
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA., Translational Genomics Research Institute, Phoenix, Arizona, USA., Bioinnovation and Genome Sciences Division, Translational Genomics Research Institute, Phoenix, Arizona, USA., Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA ., Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California, USA ., Translational Genomics Research Institute, Phoenix, Arizona, USA .